Level of COVID-19 fear in cancer patients

Atike Pınar Erdoğan*, Ferhat Ekinci, Ömer Acar and Gamze Göksel

Abstract

Background: Cancer patients are in the high-risk group of getting COVID-19 infection and experiencing a severe course. Anxiety of cancer patients about how they pass this pandemic process and how changes in the health system would influence their treatment has increased together with the COVID-19 pandemic. Influence of COVID-19 on psychology of cancer patients is also a subject needed to be investigated as well as its course and prognosis. Thus, it is aimed to measure fear levels of cancer patients by a validated scale. Patients accepting to fill in the validated Fear of COVID-19 (FCV-19S) scale were included in our study. Higher scores obtained from the scale means high level of COVID-19 fear was experienced.

Results: A total of 66.8% of 486 patients expressed that they are very afraid of coronavirus, and 66.3% expressed that they fear from losing their lives due to coronavirus. The level of fear in the patient group having adjuvant therapy has been found statistically to be significantly higher compared with groups having neoadjuvant and metastatic/palliative therapy (p: 0.004).

Conclusions: Because the increase of level of fear may lead to vital outcomes such as weakening of immune system, disturbance of treatment compliance, and worsening of prognosis, a psychological approach to cancer patients is compulsory in order to prevent fear of COVID-19 infection.

Keywords: Cancer, Coronavirus disease 2019 (COVID-19), Pandemic, Fear, Psychology

Background

COVID-19 pandemic has affected the health system throughout the world, and cancer patients are one of the specific groups in this system. Fear is a characteristic feature differentiating contagious disease from others. This fear may also bring other psychosocial difficulties as it is associated with the rate of transmission, morbidity, and mortality of the invisible factor, as well as cause stigma and isolation [1].

Although researches about psychosocial influences of infectious epidemics appearing in different regions of the world in the past are few, they may guide us in this pandemic process. Depression, anxiety, panic attacks, psychomotor agitation, psychotic manifestations, delirium, and thoughts of suicide have been determined in China during Severe Acute Respiratory Syndrome (SARS) [2].

Psychiatric signs due to SARS have been seen in 22.9% of people applying to the primary (first step) health system in Singapore during SARS, and signs of post-traumatic stress syndrome have been observed in a ratio of 25.8%. Psychiatric signs have been observed more especially in young people and those thinking that they were contagious [3]. Increase of fear level interrupts reasonable decision-making and may lead to lethal consequences such as rejection of oncological therapies in a special population such as cancer patients. Besides stress caused by situations such as facing death with having the diagnosis of cancer, social interactions and changes in body image, coincidences of follow-up, and treatment processes with COVID-19 pandemic makes these patients anxious. Cancer patients experience a period that they become very anxious due to reasons such as other concomitant diseases, taking immunosuppressive treatment, increased risk of infection, postponing surgical interventions, switching health service personnel to other areas or absence of health provider due to becoming ill, not
being able to use systems such as telemedicine exclusively. Anxiety of cancer patients increased together with COVID-19 pandemic towards how they will cope with this pandemic process and how changes in the health system due to this infection would influence their therapies [4]. Main problems faced by cancer patients due to the pandemic can be summarized as the possibility of catching disease upon going to and returning from the hospital, difficulty of accessing treatments because of travel restrictions, change of treatment units because of conversion of some hospitals into pandemic hospitals.

More severe signs and complications have been seen in cancer patients with diagnosis of COVID-19 compared with ones not having diagnosis of cancer [5]. While their anxiety related to the course of cancer and treatment was high before COVID-19, anxiety level of patients increases due to the information that the virus influences worse especially the elderly, those with lung cancer, and those with impaired immune system. They experience a challenging period for the psychological aspect by remaining between the requirement for taking life-saving treatments on the one hand and being subjected to risk of contagion on the other hand. It is known that fear and anxiety decrease quality of life and negatively affect the compliance for cancer treatment in cancer patients [6].

While knowledge about the diagnosis process of cancer patients during the COVID-19 pandemic and about how the treatment needs to be planned, there is no sufficient data about psychological problems experienced/to be experienced by cancer patients during pandemic period. Thus, evaluation of fear of COVID-19 in cancer patients by the FCV-19S (Fear of COVID-19), which is a brief, easily understood, easy-to-apply scale used in too many different populations, has come to the agenda now.

It has been aimed in this study that the level of COVID-19 fear of patients who are currently taking and who had completed treatment from our clinic would be evaluated by a validated scale and that its correlation with the type, duration, and other demographic characteristics of cancer disease would be investigated.

Methods
Patients who presented to the outpatient unit of Manisa Celal Bayar University Medical Oncology Clinic were invited to participate in the survey. Patients who accepted to fill in the Fear of COVID-19 (FCV-19S) scale and sign the informed consent form were included in our study. Demographic and clinical information such as age, gender, type of cancer, age of application, disease stage, and treatments received have been obtained from file records. The FCV-19S scale designed by Ahorsu et al. and validated by many studies was applied to patients [7] (Appendix). The Turkish language form of the scale adapted by Bakioğlu et al. was used [8]. Scores to be obtained from this scale, in which 7 expressions associated with COVID-19 fear were included, where a 5-unit (quinary) Likert (1 (I definitely disagree) to 5 (I definitely agree)) grading was used, range between 7 and 35. Higher scores obtained from the scale means high level of COVID-19 fear was experienced.

Sample size was estimated based on a hypothetical prevalence of fear (considering 50% of prevalence) with a 5% margin of error to be tolerated at the 95% level of confidence, 80% power of the test, and 95% response rate. On this basis, a total sample size of 461 was required.

While findings acquired in the study were evaluated, SPSS (Statistical Package for Social Sciences) for Windows 16.0 program was used for statistical analyses. Compliance of parameters to distribution has been evaluated by the Kolmogorov–Smirnov test while study data were evaluated. Descriptive statistics have been prepared as to include frequency (n), average, standard deviation, minimum, median, and maximum values. Frequency and percentages have been given for categorical variables. The Kruskal–Wallis test was used for comparing parameters not showing normal distribution in quantitative data and Mann–Whitney U test was used for comparing two groups. Spearman’s rho correlation test analysis was used for comparing correlation between quantitative data. Results were evaluated at 95% confidence interval and significance at p < 0.05 level.

Results
Of the 486 patients included in the study, 324 were females (66.7%) and 162 were males (33.3%). The median age was 55.8 (range 18–85) and 131 patients (27.0%) were above 65 years old. Majority of patients (44.2%) has had the diagnosis of breast cancer. While 273 patients (56.2%) had early-stage disease, 164 patients (33.7%) were at a metastatic stage and 49 patients (10.1%) at a local-advanced stage. The number of patients having active cytotoxic chemotherapy at the time of study was 146 (30%).

When responses given according to articles of FCV-19S were examined separately, 66.8% of patients have expressed that they fear very much from coronavirus, and 66.3% have expressed that they fear from losing their lives due to coronavirus (Table 1).

Any statistically significant difference has not been found between median scale scores of COVID-19 fear level according to age, gender, age of diagnosis, diagnostic groups, history of chemotherapy, history of radiotherapy, status of currently having chemotherapy, being a control patient, and disease stage (p > 0.05) (Table 2).

When it is examined according to the purpose of having treatment, fear level in patients having adjuvant...
therapy has been found to be statistically significantly higher compared with groups having neoadjuvant and metastatic/palliative therapy \((p: 0.004)\) (Table 3).

Targeted therapies being taken by patients have been examined by dividing them into subgroups as hormonotherapy, immunotherapy, tyrosine kinase inhibitor, and monoclonal antibody. Some patients have combination therapies. Fear level in the group having hormonotherapy was found to be statistically significantly higher than other subgroups \((p: 0.006)\) (Table 4).

When we grouped and examined patients according to the duration from the diagnosis of cancer until the time they answered the FCV-19S scale, it has been observed that the fear level in patients under follow-up for more than 10 years was higher numerically; but this difference has not reached to statistically significant value \((p: 0.417)\) (Fig. 1).

When we examined patients by grouping them according to whether a metastasis is present or not and according to time from the date of metastasis development until the time of answering the FCV-19S scale, median fear level in non-metastatic patients and in patients having a metastatic disease for more than 5 years has been found to be higher numerically; but this difference has not

---

### Table 1: Distribution of answers according to articles of Fear of COVID-19 (FCV-19S) scale

| Substance                                                                 | Response          | Sample size | Percentage |
|---------------------------------------------------------------------------|-------------------|-------------|------------|
| I am most afraid of coronavirus-19.                                       | Don't agree at all| 53          | 10.9       |
|                                                                            | Agree a little    | 72          | 14.8       |
|                                                                            | Hesitant          | 36          | 7.4        |
|                                                                            | Mostly agree      | 109         | 22.4       |
|                                                                            | Agree completely  | 216         | 44.4       |
| It makes me uncomfortable to think about coronavirus-19.                  | Don't agree at all| 39          | 8.0        |
|                                                                            | Agree a little    | 83          | 17.1       |
|                                                                            | Hesitant          | 47          | 9.7        |
|                                                                            | Mostly agree      | 112         | 23.0       |
|                                                                            | Agree completely  | 205         | 42.2       |
| My hands become clammy when I think about coronavirus-19.                 | Don't agree at all| 163         | 33.5       |
|                                                                            | Agree a little    | 104         | 21.4       |
|                                                                            | Hesitant          | 39          | 8.0        |
|                                                                            | Mostly agree      | 71          | 14.6       |
|                                                                            | Agree completely  | 109         | 22.4       |
| I am afraid of losing my life because of coronavirus-19.                  | Don't agree at all| 62          | 12.8       |
|                                                                            | Agree a little    | 66          | 13.6       |
|                                                                            | Hesitant          | 36          | 7.4        |
|                                                                            | Mostly agree      | 137         | 28.2       |
|                                                                            | Agree completely  | 185         | 38.1       |
| When watching news and stories about coronavirus-19 on social media, I    | Don't agree at all| 65          | 13.4       |
| become nervous or anxious.                                                | Agree a little    | 76          | 15.6       |
|                                                                            | Hesitant          | 31          | 6.4        |
|                                                                            | Mostly agree      | 141         | 29.0       |
|                                                                            | Agree completely  | 173         | 35.6       |
|                                                                            | Don't agree at all| 199         | 40.9       |
|                                                                            | Agree a little    | 75          | 15.4       |
|                                                                            | Hesitant          | 32          | 6.6        |
|                                                                            | Mostly agree      | 67          | 13.8       |
|                                                                            | Agree completely  | 113         | 23.3       |
|                                                                            | Don't agree at all| 181         | 37.2       |
|                                                                            | Agree a little    | 98          | 20.2       |
|                                                                            | Hesitant          | 31          | 6.4        |
|                                                                            | Mostly agree      | 61          | 12.6       |
|                                                                            | Agree completely  | 115         | 23.7       |
reached to a statistically significant value (23.49 and 28.5, respectively; \( p: 0.350 \)) (Fig. 2).

**Discussion**

While COVID-19 pandemic takes place as the first pandemic of the 21st century in the history of medicine, it has also caused a lot of changes within the health system unavoidably. It is not difficult to guess that the anxiety of cancer patients has increased about how they pass this pandemic period and how changes in the health system due to this infection would influence their therapies together with COVID-19 pandemic [9]. While their anxiety was high related to the course of cancer and treatment before COVID-19, anxiety level of patients and their relatives increases now because of the information that the virus influences badly especially the people with advanced age, those having lung cancer, and those with impaired immune system [10].

Differently from the general population, it is known that fear and anxiety disorders in cancer patients are not associated with age or gender [11]. In our study, while the median score of the fear scale of male patients was 21.7, it was found to be 23.2 in females and mildly higher than males in numerical terms; however, this difference has not expressed any statistical significance (\( p: 0.085 \)). In another study using the FCV-19S scale in cancer patients, the fear level has been found to be higher in females compared with males (22.2 vs. 17.8, \( p<0.05 \)) [12].

While the fear score of 131 patients in over-65 years old group that is considered to be at risk for COVID-19 according to data in the literature was 23.7, the score of 355 patients at 65 years old and below has been determined as 22.3 (\( p: 0.316 \)) [13]. Again, in a study where

**Table 2** General demographic and clinical characteristics of patients

| Age groups       | Sample size | FCV-19S score ± SD | \( p \) value |
|------------------|-------------|--------------------|---------------|
| Under 50 years old | 139         | 22.27 ± 8.09       | 0.316         |
| 50–65 years old  | 216         | 22.35 ± 8.34       |               |
| Above 65 years old | 131         | 23.78 ± 9.47       |               |

| Gender          | Sample size | FCV-19S score ± SD | \( p \) value |
|-----------------|-------------|--------------------|---------------|
| Male            | 162         | 21.71 ± 9.22       | 0.085         |
| Female          | 324         | 23.21 ± 23.21      |               |

| Tumor type       | Sample size | FCV-19S score ± SD | \( p \) value |
|------------------|-------------|--------------------|---------------|
| Breast           | 215         | 23.45 ± 8.23       | 0.435         |
| Gastrointestinal system | 113       | 22.37 ± 8.76       |               |
| Urogenital system | 73          | 22.73 ± 8.35       |               |
| Head–neck        | 19          | 19.74 ± 8.83       |               |
| Other            | 33          | 21.97 ± 9.36       |               |

| Disease stage   | Sample size | FCV-19S score ± SD | \( p \) value |
|-----------------|-------------|--------------------|---------------|
| Early           | 273         | 23.61 ± 8.3        | 0.278         |
| Local advanced  | 49          | 22.63 ± 7.75       |               |
| Metastatic      | 164         | 21.24 ± 9.14       |               |

| Control patient | Sample size | FCV-19S score ± SD | \( p \) value |
|-----------------|-------------|--------------------|---------------|
| No              | 368         | 22.55 ± 8.66       | 0.448         |
| Yes             | 118         | 23.21 ± 8.41       |               |

| Does he/she take active cytotoxic KT? | Sample size | FCV-19S score ± SD | \( p \) value |
|--------------------------------------|-------------|--------------------|---------------|
| No                                   | 340         | 22.85 ± 8.59       | 0.617         |
| Yes                                  | 146         | 22.38 ± 8.63       |               |

**Table 3** Evaluation of scores of COVID-19 (FCV-19S) fear scale according to purpose of treatment

| Aim of treatment     | Sample size | Mean ± SD | Median | Lowest | Highest | \( p \) value |
|----------------------|-------------|-----------|--------|--------|---------|---------------|
| Adjuvant             | 169         | 24.15 ± 8.13 | 23.00  | 7.00   | 35.00   | 0.004         |
| Neoadjuvant          | 29          | 23.45 ± 7.33 | 23.00  | 11.00  | 35.00   |               |
| Metastatic-palliative| 136         | 20.91 ± 9.22 | 20.00  | 7.00   | 35.00   |               |

**Table 4** Evaluation of scores of Fear of COVID-19 (FCV-19S) scale according to groups having targeted therapies

| Ones taking targeted therapies | Sample size | Mean ± SD | Median | Lowest | Highest | \( p \) value |
|--------------------------------|-------------|-----------|--------|--------|---------|---------------|
| Hormonotherapy                 | 124         | 24.28 ± 7.91 | 23.00  | 7.00   | 35.00   | 0.006         |
| Immunotherapy                  | 11          | 17.45 ± 9.23 | 14.00  | 7.00   | 35.00   |               |
| Tyrosine kinase inh            | 31          | 22.06 ± 9.76 | 23.00  | 7.00   | 35.00   |               |
| Monoclonal antibody            | 57          | 20.49 ± 9.23 | 19.00  | 7.00   | 35.00   |               |
persons at 60 years old and above were included, it has been seen that fear scores of elderly who feel themselves isolated from others and whose close friends and family were diagnosed COVID-19 were higher [14]. It appears that older adults isolated due to immunosuppression related to cancer treatment before the pandemic required closer follow-up for their psychosocial aspect during the period of the COVID-19 pandemic.

There are studies in the literature indicating that depression and anxiety levels are different according to the type of cancer. It is thought that patients having lung cancer and gynecological cancers are affected more frequently [15]. In our study group, breast cancer, gastrointestinal system cancers, and urogenital cancers are dominant according to rank of frequency; levels of fear have been found as 23.45, 22.37, and 22.73, respectively. Although the fear level is numerically high in patients with breast cancer, any statistically significant difference has not been observed (p: 0.435). Vanni et al. has examined the influence of their anxiety levels on treatment
decisions of patients with breast cancer in the COVID-19 course, and they have indicated that fear occurring due to the contagion risk of COVID-19 infection may be a reason for rejecting surgical intervention [16]. This type of data shows that evaluation of the psychological status is also important in the follow-up and treatment process as well as evaluation of tumor in cancer patients.

Cancer patients are prone to infection due to their immunosuppressed condition caused by the disease itself and treatments such as chemotherapy, radiotherapy, and surgery they had. For this reason, cancer patients form a high-risk population for the aspect of COVID-19. According to the knowledge coming from a study including two small and heterogeneous patient groups, it has been reported that 39–54% of cancer patients catching COVID-19 had severe clinical course (treatment in intensive care unit or death) [17]. The outcome of those having cytotoxic treatment 2–4 weeks before development of symptoms of COVID-19 is worse [18]. In our study, any difference has not been determined between fear levels of 146 patients having cytotoxic chemotherapy on the day the scale was used compared with those having other oncological treatments or patients who completed treatment and come for control visits (22.3 and 22.85, respectively). In the study of Sigorski et al., the FCV-19S scale has been used at the second month of the pandemic, and fear level of cancer patients having cytotoxic therapy has been reported as 18.5 which is lower than our population [19]. At the time our study was conducted, the pandemic has completed its 11th month in our country, and the total number of cases has exceeded 2.5 million, and the number of daily new cases was around an average of 7500 [20]. Prolongation of the pandemic process and increase of uncertainties have increased the level of fear, and this may cause the fact that scores have been found higher in our study.

The fear level of 124 patients having hormonal agents which have been considered as one of the safe oncological treatments has been found to be higher compared with patients having immunotherapy, tyrosine kinase inhibitor, and monoclonal antibody during the period of the COVID-19 pandemic, and this difference is statistically significant ($p<0.006$, scores are 24.2 vs. 17.4, 22, 20.4, respectively). This difference can be explained by the fact that fear level of these patients is higher, most of whom have early-stage disease, because hormonal agents are used for adjuvant purpose in breast cancer.

While the fear scale score of patients not having metastasis was 23.49, score of those having metastatic disease for 1–5 years has been determined to be 21.03. This observation made us think that metastatic cancer patients have vital anxieties of more priority than those with COVID-19 during the struggle with cancer. The higher level of fear, due to COVID-19, of early-stage patients who have expectations for cure may be related to the anxiety that successful result they can obtain from cancer therapy may be interrupted by COVID-19 infection.

Hemmington et al. have demonstrated that there are severe mental health problems in patients with advanced-stage cancer; in our study, while fear scale scores of patients with diagnosis of metastasis for 0–6 months, 6–12 months, and 1–5 years are 20.70, 21.35, and 21.03, respectively, the score of 6 patients having metastatic diseases for more than 5 years has the highest score with an average of 28.5; but further interpretation has not been made because the number of patients is small in this group ($p>0.350$) [6].

It is known that depression and anxiety are at a high level in the acute period when cancer diagnosis was made, and it would decrease with time [21]. While the score from the fear scale of patients included in the study was 22.09 whose duration from the diagnosis is between 5 and 10 years, a score of 23.18 has been determined from those having the diagnosis within the last 6 months. Although it does not reach to a statistically significant value, it can be said that patients newly diagnosed with cancer may cause an increase of COVID-19 fear level, and perception level of patients for both diseases might be influenced consistently with the literature.

Our study has several limitations. Primarily, findings may not be applied to the general oncological patient population because it was conducted in a tertiary oncology clinic, and participation was based on voluntariness principle. Another point is the use of psychotropic drugs that may influence perception of patients towards expression in the scale has not been recorded. Making an evaluation in a relatively large sample of patients in different age groups and tumor types by a validated scale is the strong side of our study.

Cancer patients were familiar with wearing masks in the community, staying away from crowds, and showing isolation behavior also prior to the COVID-19 pandemic. However, because cancer patients, who take precautions to avoid getting infected for a long time, experienced some kind of “precaution tiredness” with the pandemic process, disturbance of treatment compliance and emergence of mental health problems or exacerbation of existing ones are subjects for question. Psychosocial approaches or psychological evaluations towards the mental health of cancer patients should certainly be made for each patient during the pandemic period. Worsening of the immune system due to increase of anxieties and irritability, lack of motivation, tiredness, fatigue, and
signs of depression may appear at this period, and these may influence the treatment process and even the prognosis [22]. Randomized controlled studies on how the patients’ anxiety symptoms related to the fear of COVID-19 affect their general condition, laboratory values, and drug responses are needed.

**Conclusions**
In order to prevent fear of COVID-19 infection which takes patients away from life-saving treatments and which causes death, psychological evaluation of cancer patients is compulsory. Researches about influence of COVID-19 on psychology of cancer patients are needed as well as its course and prognosis in cancer patients.

**Appendix**
Fear of Coronavirus-19 Scale
1. I am most afraid of coronavirus-19.
2. It makes me uncomfortable to think about coronavirus-19.
3. My hands become clammy when I think about coronavirus-19.
4. I am afraid of losing my life because of coronavirus-19.
5. When watching news and stories about coronavirus-19 on social media, I become nervous or anxious.
6. I cannot sleep because I’m worrying about getting coronavirus-19.
7. My heart races or palpitates when I think about getting coronavirus-19.

The participants indicate their level of agreement with the statements using a five-item Likert-type scale. Answers included “strongly disagree,” “disagree,” “neither agree nor disagree,” “agree,” and “strongly agree”. The minimum score possible for each question is 1, and the maximum is 5. A total score is calculated by adding up each item score (ranging from 7 to 35). The higher the score, the greater the fear of coronavirus-19.

**Abbreviations**
FCV-19S: Fear of COVID-19 scale; SARS: Severe Acute Respiratory Syndrome.

**Acknowledgments**
We are grateful to all our patients who participated in the study.

**Authors’ contributions**
APE and FE designed the study, drafted the manuscript, and designed the figures. ÖA and GG aided in interpreting the results and supervised all the process. All authors had full access to the data, contributed to the study, approved the final version for publication, and take responsibility for its accuracy and integrity.

**Funding**
None

**Availability of data and materials**
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Declarations**

**Ethics approval and consent to participate**
Our study was conducted according to the criteria set by the Declaration of Helsinki, and MCB University Faculty of Medicine Ethics Committee approved the study (approval date and no: 20/01/2021—20.478.486)

**Consent for publication**
Not applicable

**Competing interests**
The authors declare that they have no competing interests.

**Received**
22 November 2021    **Accepted**
17 January 2022

**Published online**
28 January 2022

**References**
1. Pappas G, Kiniuze U, Giannakis P, Falagas ME (2009). Psychosocial consequences of infectious diseases. Clin Microbiol Infect 15:743–747
2. Hsieh KY, Kao WT, Li DJ, Lu WC, Tsai KY, Chen WJ et al (2020). Mental health in biological disasters: from SARS to COVID-19. Int J Soc Psychiatry In press
3. Sima K, Chanb YH, Chongc PN, Chuana SWS (2010). Psychosocial and coping responses within the community health care setting towards a national outbreak of an infectious disease. J Psychosom Res 68:195–202
4. Guven DC, Sahin TK, Aktepe OH, Yildirim HC (2020). Perspectives, knowledge, and fears of cancer patients about COVID-19. Front Oncol 10:1–6
5. Lee LYW, Cazier JB, Angelis V, Arnold R, Bish V, Campton NA et al (2020). COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet 395:1919–1926
6. Hemmington A, Huang D, Coomarasamy C, Young MJ, Consendine NS, Reynolds LM (2020). When mental illness and cancer collide: an investigation of the predictors of outcomes for cancer patients with a history of mental health problems. Psychooncology. 29:525–531
7. Ahorsu DK, Lin CY, Imani V, Safifari M, Griffiths MD, Pakpour AH (2020). The Fear of COVID-19 Scale: Development and Initial Validation. Int J Ment Health Addict. https://doi.org/10.1007/s11469-020-00270-8
8. Bakioğlu F, Korkmaz O, Ercan H (2020). Fear of COVID-19 and positivity: mediating role of intolerance of uncertainty, depression, anxiety, and stress. Int J Ment Heal Addict In press
9. Burki TK (2020). Cancer guidelines during the COVID-19 pandemic. Lancet Oncol 21:629–630
10. Gregucci F, Calandrino M, Surgo A, Carbonara R, Bonaparte I. (2020). Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information.
11. Stark DPH, House A (2000). Anxiety in cancer patients. Br J Cancer 83:1261–1267
12. Grajek M, Dzialach E, Buczkowska M, Górska M, Nowara E (2021). Feelings related to the COVID-19 pandemic among patients treated in the oncology clinics (Poland). Front Psychol 12:1–6
13. Adashek J, Hajar J, Chemaly R, Kurzrock R (2020). Are cancer patients at higher risk of death with COVID-19? Are cancer patients at higher risk of death with coronavirus disease-19? J Immunother Precis Oncol 00
14. Mistry SK, Ali ARMA, Akther F, Yadav UN, Harris MF (2021). Exploring fear of COVID-19 and its correlates among older adults in Bangladesh. Glob Health 17:1–9
15. Linden W, Vodermaier A, MacKenzie R, Greig D (2012). Anxiety and depression after cancer diagnosis: prevalence rates by cancer type,
gender, and age. J Affect Disord 141:343–351. https://doi.org/10.1016/j.jad.2012.03.025
16. Vanni G, Materazzo M, Pellicciaro M, Ingallinella S, Rho M, Santori F et al (2020) Breast cancer and COVID-19: the effect of fear on patients’ decision-making process. In Vivo (Brooklyn) 34:1651–1659
17. Chandrasekaran B, Fernandes S (2020) Since January 2020 Elsevier has created a COVID-19 resource Centre with free information in English and mandarin on the novel coronavirus. The COVID-19 resource Centre is hosted on Elsevier connect, the company’s public news and information website. Diabetes Metab Syndr 14(4):337–339
18. Al-Shamsi HO, Alhazzani W, Alhuraiji A, Coomes EA, Chemaly RF, Almuhanna M et al (2020) A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID-19) pandemic: an international collaborative group. Oncologist 25:936–945
19. Sigorski D, Sobczuk P, Osmola M, Kuć K, Walertzak A, Wilk M et al (2020) Impact of COVID-19 on anxiety levels among patients with cancer actively treated with systemic therapy. ESMO Open 5:1–8
20. Genel Koronavirüs Tablosu [Internet]. T.C. Sağlık Bakanl. 2021; Available from: https://covid19.saglik.gov.tr/TR-66935/genel-koronavirus-tablosu.html
21. Krebber AMH, Buffart LM, Kleijn G, Riepma IC, De Bree R, Leemans CR et al (2014) Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments. Psychooncology. 23:121–130
22. Lawrence D, Hancock KJ, Kisely S (2015) Cancer and mental illness. Key Issues Ment Heal 179:88–98

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.